C-type Natriuretic Peptide (CNP)
Evidence: CCardiovascular / Vascular
Evidence Snapshot
What this grade covers
Applies to native CNP evidence only. Vosoritide is a modified CNP analogue represented as contextual evidence only and does not contribute to or upgrade this grade.
Regulatory Context
Native C-type Natriuretic Peptide is not itself an FDA-approved drug product. A modified analogue, Vosoritide (marketed as Voxzogo), is FDA-approved as a separate regulated product for a specific pediatric indication -- this is analogue-product approval, not approval of native CNP.
Research Takeaway
C-type Natriuretic Peptide (CNP) is a distinct natriuretic peptide and must not be merged with ANP, BNP, proCNP/NT-proCNP, or engineered NPR-B agonist analogues.
Evidence boundary: Exact CNP molecular form should be recorded per source when CNP-22 and CNP-53 distinctions matter.
See all 6 evidence claims →Quick Summary
C-type Natriuretic Peptide (CNP) is a vascular/paracrine natriuretic peptide with direct human infusion evidence showing dose- and protocol-dependent vascular and renal effects. Vosoritide is a clinically proven and FDA-regulated CNP analogue, but its modified sequence and product programme remain contextual evidence rather than proof of native-CNP therapeutic efficacy.
Mechanism & Research Overview
C-type Natriuretic Peptide (CNP) is a vascular/paracrine natriuretic peptide with direct human infusion evidence showing dose- and protocol-dependent vascular and renal effects. Vosoritide is a clinically proven and FDA-regulated CNP analogue, but its modified sequence and product programme remain contextual evidence rather than proof of native-CNP therapeutic efficacy.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
C-type Natriuretic Peptide (CNP) is a distinct natriuretic peptide and must not be merged with ANP, BNP, proCNP/NT-proCNP, or engineered NPR-B agonist analogues.
Does not establish
Evidence boundary: Exact CNP molecular form should be recorded per source when CNP-22 and CNP-53 distinctions matter.
Sources: Effects of intravenously administered C-type natriuretic peptide in humans; Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure
Supported
Exact CNP has been directly administered in human studies and produces measurable vascular, hemodynamic, and renal/natriuretic physiology.
Does not establish
Evidence boundary: Findings vary by dose/protocol and do not establish chronic therapeutic efficacy.
Sources: Effects of intravenously administered C-type natriuretic peptide in humans; Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans; Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure; C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels; Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers
Supported
Human CNP infusion findings are not uniformly positive across dose ranges and protocols.
Does not establish
Evidence boundary: A low-dose study reported no major cardiac/renal effects while other studies found vasodilatory or natriuretic responses.
Sources: Effects of intravenously administered C-type natriuretic peptide in humans; Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans; Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure
Supported
Human forearm studies support direct vasodilator activity of CNP with a hyperpolarization-related component.
Does not establish
Evidence boundary: Regional vascular mechanisms do not establish whole-body treatment efficacy.
Sources: Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure; C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels
Supported
Vosoritide is a modified CNP analogue with an established achondroplasia clinical programme, but its efficacy, safety, approval, and dosing cannot be transferred to native CNP.
Does not establish
Evidence boundary: Vosoritide is classified only as ANALOGUE_PROGRAM_CONTEXT for this page.
Sources: Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial; VOXZOGO (vosoritide) FDA prescribing information
Supported
FDA approval of VOXZOGO (vosoritide) is approval of the modified CNP analogue product, not approval of native C-type Natriuretic Peptide.
Does not establish
Evidence boundary: Do not rewrite analogue-product approval as molecule-wide approval of CNP.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Native CNP can alter vascular tone, blood pressure, heart rate, and renal handling during experimental administration.Safety Consideration
Human responses vary with dose and protocol.Safety Consideration
Vosoritide adverse effects/labeling are analogue-product evidence, not a native-CNP safety profile.Safety Consideration
Long-term systemic safety of native CNP administration is not established by the frozen source set.
Research Areas Being Studied
Research areas discussed on this page reflect the Cardiovascular / Vascular category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial (2020):
- Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers (2015):
- C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels (2001):
- Effects of intravenously administered C-type natriuretic peptide in humans (1998):
- Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans (1998):
- Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure (1994):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial | 2020 | 121 children with achondroplasia; randomized placebo-controlled | Vosoritide increased annualized growth velocity versus placebo in achondroplasia. | ||
| Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers | 2015 | Six healthy volunteers; double-blind three-way (or three-day) crossover comparing ANP, BNP, and CNP | Directly compared cerebral/systemic vascular responses to three natriuretic peptides (ANP, BNP, CNP) on separate study days/arms. | ||
| C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels | 2001 | Human forearm resistance-vessel physiology | Human CNP vasodilation was studied with mechanistic blockade, supporting a hyperpolarization-related component. | ||
| Effects of intravenously administered C-type natriuretic peptide in humans | 1998 | Five healthy volunteers | IV CNP caused transient blood-pressure reduction, increased heart rate, and measurable diuretic/natriuretic effects. | ||
| Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans | 1998 | Healthy volunteers | Low-dose CNP did not materially change cardiac/renal function under protocol. | ||
| Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure | 1994 | Human forearm vascular studies including chronic heart failure | CNP produced local vasodilatory effects distinguishable from ANP. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| VOXZOGO (vosoritide) FDA prescribing information | Official product labeling defines Vosoritide as a CNP analogue and documents its regulated indication and product safety information. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-25.
Follow research updates for C-type Natriuretic Peptide (CNP)
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.